Transdermal therapeutic delivery systems with a butenolide

• US 20040166148A1
• Filed: 02/03/2004
• Published: 08/26/2004
• Est. Priority Date: 02/07/2003
• Status: Abandoned Application

• Current Assignee: Novosis AG (Pharma Strategy Partners GmbH)
• Original Assignee: Novosis AG (Pharma Strategy Partners GmbH)
• Inventors: McLeod, Sarah, Meyer, Elisabeth, Woess, Angelika, Schenk, Dirk
• Application Number:
  US10/770,819
• Publication Number:
  US 20040166148A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 31/48 Ergoline derivatives, e.g. lysergic acid, ergotamine
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention concerns a transdermal therapeutic delivery system (TTDS) with butenolide.

Claims

1. Transdermal therapeutic delivery system (TTDS) comprising one, two or more drugs and a butenolide.

2. System according to claim 1 wherein the butenolide is a α

-angelica lactone (4-hydroxy-3-pentenoic acid gamma-lactone) or β

-angelica lactone (4-hydroxy-2-pentenoic acid gamma-lactone).

6. System according to claim 1, 2, 3, 4, 5 or a combination thereof wherein the drug(s) comprises (comprise) an N-atom susceptible to oxidation to an N-oxide.

7. System according to claim 1, 2, 3, 4, 5, 6 or a combination thereof wherein the drug(s) is (are) an alkaloid, especially an alkaloid selected from the group consisting of opioids and/or ergot alkaloids.

8. System according to claim 1, 2, 3, 4, 5, 6, 7 or a combination thereof wherein the drug(s) is (are) a quinoline and/or a pyridine derivative.

9. System according to claim 1, 2, 3, 4, 5, 6, 7, 8 or a combination thereof wherein the system is of the matrix-type or of the reservoir-type.

10. System according to claim 9 wherein the system comprises a backing layer, a removable protecting layer and a matrix or a reservoir in between the backing layer and the protecting layer.

11. System according to claim 9 and/or 10 wherein the system is of the reservoir-type and comprises a membrane.

12. System according to claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or a combination thereof comprising a butenolide or a precursor thereof as antioxidant.

13. System according to claim 12 wherein the amount of the butenolide is adjusted to the intended time of storage.

14. System according to claim 12 and/or 13 wherein

for use of the system in a temperate climate the molar ratio of drug(s):

precursor or butenolide is of from 1;

4.1 to 1;

5 and

for use of the system in a subtropical or tropical climate the molar ratio of drug(s);

precursor or butenolide is of from 1;

4.1 to 1;

15.

3. Transdermal therapeutic delivery system (TTDS) comprising one, two or more drugs and a precursor of a butenolide, wherein the following drugs are excluded as drug:

buprenorphin-base, desoxy peganin and an addition salt of levulinic acid and a morphin alkaloid of the following formula

5. System according to claim 3 or 4 wherein the precursor of the butenolide is levulinic acid or 5-amino-levulinic acid.

4. Transdermal therapeutic delivery system (TTDS) comprising one, two or more drugs and a precursor of a butenolide wherein the mole ratio of drug(s):

precursor is of from 1;

4.1 to 1;

15 and especially 1;

4.5 to 1;

10.